ArticleFrontiers in endocrinology2023

Sodium glucose co-transporter 2 (SGLT2) inhibition via dapagliflozin improves diabetic kidney disease (DKD) over time associatied with increasing effect on the gut microbiota in db/db mice.

Jiajia Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.